Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.62 -3.1%	$39.29	$26.20 ▼ $63.50	$1.69B	1.43	729,462 shs	389,711 shs
BEAM Beam Therapeutics	$16.85 -0.1%	$18.73	$13.52 ▼ $35.25	$1.70B	2.22	2.09 million shs	1.74 million shs
SLDB Solid Biosciences	$5.62	$5.80	$2.41 ▼ $9.37	$437.62M	2.44	1.87 million shs	536,801 shs
TVTX Travere Therapeutics	$17.70 +1.5%	$16.23	$8.98 ▼ $25.29	$1.58B	0.74	1.65 million shs	3.21 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.21%	+4.91%	-4.72%	+0.27%	-20.49%
BEAM Beam Therapeutics	+1.32%	+4.98%	-19.06%	+3.31%	-35.87%
SLDB Solid Biosciences	-1.58%	-0.71%	-19.94%	+70.30%	-38.58%
TVTX Travere Therapeutics	0.00%	-2.95%	+13.25%	+13.39%	+92.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.7676 of 5 stars	4.4	3.0	2.7	4.2	0.0
BEAM Beam Therapeutics	2.046 of 5 stars	3.5	0.0	2.2	2.5	0.6
SLDB Solid Biosciences	3.3566 of 5 stars	4.6	2.0	2.6	1.7	0.6
TVTX Travere Therapeutics	2.3489 of 5 stars	3.4	3.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.88	Moderate Buy	$97.29	165.66% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	187.56% Upside
SLDB Solid Biosciences	3.17	Buy	$15.00	166.90% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$33.43	88.86% Upside

Current Analyst Ratings Breakdown

Latest SLDB, BEAM, APGE, and TVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/28/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $47.00
8/28/2025	APGE Apogee Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $87.00
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/14/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $13.00
8/13/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $14.00
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/10/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $31.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
BEAM Beam Therapeutics	$63.52M	26.83	N/A	N/A	$10.35 per share	1.63
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.32 per share	N/A
TVTX Travere Therapeutics	$233.18M	6.77	N/A	N/A	$0.37 per share	47.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	11/11/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.80	N/A	N/A	N/A	N/A	-69.70%	-56.74%	11/5/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-717.68%	-30.69%	10/30/2025 (Estimated)

Latest SLDB, BEAM, APGE, and TVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
BEAM Beam Therapeutics	N/A	6.75	6.75
SLDB Solid Biosciences	N/A	9.34	9.34
TVTX Travere Therapeutics	9.50	2.00	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BEAM Beam Therapeutics	99.68%
SLDB Solid Biosciences	81.46%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BEAM Beam Therapeutics	3.50%
SLDB Solid Biosciences	1.90%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
SLDB Solid Biosciences	100	77.87 million	76.39 million	Optionable
TVTX Travere Therapeutics	460	89.14 million	85.40 million	Optionable

SLDB, BEAM, APGE, and TVTX Headlines

Recent News About These Companies

Travere Therapeutics stock jumps after FDA approves reduced monitoring for FILSPARI

August 28 at 1:25 PM | au.investing.com

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

August 27 at 5:09 PM | businesswire.com

Invesco Ltd. Lowers Position in Travere Therapeutics, Inc. $TVTX

August 27 at 3:30 AM | marketbeat.com

21,094 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Penn Capital Management Company LLC

August 26 at 6:38 AM | marketbeat.com

Wall Street Zen Downgrades Travere Therapeutics (NASDAQ:TVTX) to Hold

August 26 at 3:42 AM | marketbeat.com

Travere Therapeutics, Inc. $TVTX Shares Purchased by Charles Schwab Investment Management Inc.

August 26 at 3:19 AM | marketbeat.com

Canaccord Genuity Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

August 25 at 6:07 PM | theglobeandmail.com

Vanguard Group Inc. Reduces Stock Position in Travere Therapeutics, Inc. $TVTX

August 25 at 3:15 AM | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Cut to "Hold" at Wall Street Zen

August 25 at 2:39 AM | americanbankingnews.com

Candriam S.C.A. Takes Position in Travere Therapeutics, Inc. $TVTX

August 24, 2025 | marketbeat.com

Travere Therapeutics Earnings Call Highlights FILSPARI Success

August 23, 2025 | theglobeandmail.com

Aberdeen Group plc Raises Stock Holdings in Travere Therapeutics, Inc. $TVTX

August 22, 2025 | marketbeat.com

Nuveen LLC Makes New Investment in Travere Therapeutics, Inc. $TVTX

August 20, 2025 | marketbeat.com

Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to "Buy"

August 19, 2025 | americanbankingnews.com

Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts

August 18, 2025 | msn.com

Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to Buy

August 17, 2025 | marketbeat.com

Informed Momentum Co LLC Invests $2.69 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 14, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 13, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Analysts

August 12, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings

August 11, 2025 | marketbeat.com

Travere Therapeutics price target raised to $32 from $30 at Wedbush

August 8, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, BEAM, APGE, and TVTX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.62 -1.17 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$36.63 +0.01 (+0.03%)

As of 07:10 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.85 -0.01 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$17.05 +0.20 (+1.18%)

As of 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$5.62 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.62 0.00 (-0.09%)

As of 05:42 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$17.70 +0.26 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$17.92 +0.22 (+1.21%)

As of 07:17 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time